Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2015

View Archived Issues

Col-Treg designated by the FDA as orphan drug for the treatment of chronic non-infectious uveitis

Promising phase II results on lenvatinib in advanced medullary thyroid cancer

TC Biopharm granted CTA approval to treat cancer patients with ImmuniCell

Protalix reports positive data from second dose cohort in phase I/II trial of PRX-102

NCI grant supports planned phase II study of Yeliva for refractory or relapsed multiple myeloma

New approaches identified for Middle-East respiratory syndrome coronavirus vaccination

Next-generation CDK2/9 inhibitor CCT-68127 shows potent activity against lung cancer cells

Phase I findings confirm bioavailability of Gordagen's MELT3 formulation

FDA accepts IND and grants orphan drug designation to DTX-101 for hemophilia B

FDA grants fast track designation to MN-001 for IPF

Amgen seeks FDA approval for new delivery option for monthly administration of Repatha

AR-301 gets FDA fast track designation for acute pneumonia caused by S. aureus

Blueprint Medicines cleared to study BLU-285 in systemic mastocytosis

SK Biopharmaceuticals discovers dopamine reuptake inhibitors

Vaccibody starts phase I/IIa trial of VB10.16 in women with cervical intraepithelial neoplasia

Nimbus Lakshmi introduces TYK2 and JAK2 inhibitors

Gilead patent discloses compounds for the treatment of HIV

BioCancell's BC-819 receives FDA fast track designation in bladder cancer

Treventis reports beta-amyloid aggregation inhibitors

EMA grants orphan drug designation to Stemline's SL-401 for AML

FDA advisory committees recommend approval of Collegium's Xtampza ER

FDA approves Humira for moderate to severe hidradenitis suppurativa

HUHS-1015 potently inhibits malignant mesothelioma cell proliferation

FDA accepts first NDA for a digital medicine

Novel PI4K2A gene mutations identified in cutis laxa syndrome with choreoathetosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...